Visão geral da empresa
A clinical-stage pharmaceutical enterprise dedicated to advancing cannabinoid-based therapies, SciSparc Ltd. focuses its research and development efforts on specific therapeutic areas including Tourette syndrome, Alzheimer's disease, agitation, autism spectrum disorder, and status epilepticus. Operating within the Healthcare sector and specifically the Biotechnology industry, the company positions itself as a specialized player in the development of novel drug candidates rather than a diversified conglomerate. The entity currently maintains a market capitalization of $1.93M and reports annual revenue of $1.31M based on trailing twelve-month data. With an employee count of only 2, the organization operates at a micro-cap scale, indicating that its financial resources are heavily concentrated in R&D activities rather than large-scale manufacturing or sales infrastructure. This valuation and revenue profile suggests the company is in an early-stage development phase where capital efficiency is critical and the primary objective is to advance clinical programs toward regulatory approval rather than generating significant cash flow from commercial sales.
Saúde financeira
SciSparc Ltd. reported revenue of $1.31M over the trailing twelve months, yet this income was insufficient to cover its operational costs, resulting in a net income of $-6,480,000 and an EBITDA of $-7,029,000. The substantial disparity between the $1.31M revenue and the $-6,480,000 net income reveals a cost structure dominated by heavy research and development expenditures typical of clinical-stage biotechnology firms. The company reports N/A for free cash flow, which indicates that current cash generation from operations does not yet exceed capital expenditures, reflecting a reliance on external financing to fund operations. In terms of profitability margins, the Gross Margin stands at 38.7%, suggesting that the cost of goods sold for its drug development programs is relatively contained compared to total revenue, while the Operating Margin of -569.5% and Profit Margin of 0.0% highlight significant inefficiencies or high overhead relative to revenue scale. Regarding liquidity and leverage, the company holds $0 in debt, creating a scenario where total cash is not needed to service interest obligations, though the specific cash balance is listed as N/A. The Debt to Equity ratio is N/A due to the absence of equity or debt figures in the standard reporting format, yet the zero debt position technically implies a conservative balance sheet structure free from leverage. The Current Ratio is listed as N/A, meaning short-term liquidity ratios cannot be calculated with the provided data, but the absence of debt suggests no immediate solvency pressure from debt covenants. Finally, the Return on Equity is -1281.5% and Return on Assets is N/A, metrics that indicate the company is currently destroying shareholder value on a per-dollar-of-equity basis, a common characteristic for pre-commercial biotechnology entities burning through capital to achieve clinical milestones.
Avaliação de valorização
SciSparc Ltd. exhibits a P/E Ratio (TTM) of 0.00, which occurs because the company reports a net loss, rendering the trailing earnings multiple mathematically undefined or zero, while the Forward P/E is N/A as future earnings per share have not yet materialized or are not projected in the available data. The Price to Book ratio is 0.02, indicating that the market capitalization values the company at a fraction of its book value, which often happens when intangible assets like intellectual property are not fully reflected on the balance sheet or when the market discounts the high risk of clinical-stage assets. The Price to Sales ratio is 1.48, a metric often utilized for unprofitable growth companies, suggesting the market is willing to pay approximately 1.48 times the annual revenue for the company's future clinical potential. The EV/EBITDA ratio is N/A due to the negative earnings and lack of enterprise value components required for calculation. In terms of price volatility, the stock has traded between a 52-Week Low of $3.32 and a 52-Week High of $94.50, demonstrating extreme price fluctuations common in small-cap biotechnology stocks. Without the current share price, the exact percentage distance from the highs or lows cannot be calculated, but the range itself illustrates a high-risk investment profile where the stock can experience massive percentage moves relative to its historical trading band. The Beta is 1.33, signifying that the stock is expected to be 33% more volatile than the broader market index, meaning it will likely amplify market movements both upward and downward with greater intensity than large-cap equities.
Growth & Income
The Revenue Growth (YoY) and Earnings Growth (YoY) are both listed as N/A, preventing a direct comparison of growth rates between the top line and bottom line over the current year. In the absence of positive earnings growth, the company is not generating profits to distribute to shareholders, as evidenced by a Dividend Yield of N/A and a Payout Ratio of 0.0%. Since the company is not a dividend payer, the entire focus of its financial strategy must be on reinvesting any available capital into advancing its drug development programs for SCI-110 and SCI-210 rather than returning cash to investors. The overall growth and income profile is characterized by a lack of historical growth data and a complete absence of dividend income, reflecting the typical trajectory of a clinical-stage pharmaceutical company that prioritizes capital allocation toward R&D over current shareholder returns or revenue expansion metrics.